biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by bfwon May 30, 2018 9:21am

209 Views

Post# 28098142

RE:RE:Bioasis announces independent research publication in JCBFM

“Only MTfpep chemically conjugated to NIP228-IL-1RA had reversal at four days post dose. The magnitude of the response was very similar for all MTf-IL-1RA fusions tested (Figure 6(a)). It is of significance to note that the reversal of hyperalgesia was two to four days in length, one day more than if IL-1RA is directly injected intrathecally where the effect lasted one day.”

The peptide wins above all else...even intrathecal!

BearDownAZ wrote: Congratulations to Mark Day, the rest of BiOasis and MedImmune on this amazing study! I've been looking forward to this one for a while. Here is a direct link to the published article entitled:

"A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model."

BearDownAZ